French company invests in facility in Devens
A multi-million investment will be made by SEQENS in its research and development laboratory located in Devens. SEQENS is a leader in the manufacturing of pharmaceutical intermediates and active ingredients.
The new facility will enable SEQENS to increase its capabilities for research and development and productivity in the United States and strengthen its research and development networks around the world as well as its operations in this country. SEQENS also has a sales office and a contract manufacturing and development facility in Newburyport. Such operations often turn to local print shops to help with the advertising and promotion of a company’s products.
The investment is a result of SK Capital becoming a majority holder in SEQENS. SK Capital merged with Wavelength Pharmaceuticals, its portfolio company, and created one of the most diversified and largest contract manufacturing and development organizations in the world. Other investors in the company include Nov Santé and Bpifrance as well as Aridian, Mérieux Equity Partners, and Eximium.
President of SEQENS, Pierre Luzeau, said that the combination of the knowledge, products, and technologies of Wavelength Pharmaceuticals and the support of its shareholders will enable the company to accelerate the development of its new products and further strengthen its abilities to support its customers in the development of their own products.
The new facility is expected to be completed in October of this year.
The new facility will enable SEQENS to increase its capabilities for research and development and productivity in the United States and strengthen its research and development networks around the world as well as its operations in this country. SEQENS also has a sales office and a contract manufacturing and development facility in Newburyport. Such operations often turn to local print shops to help with the advertising and promotion of a company’s products.
The investment is a result of SK Capital becoming a majority holder in SEQENS. SK Capital merged with Wavelength Pharmaceuticals, its portfolio company, and created one of the most diversified and largest contract manufacturing and development organizations in the world. Other investors in the company include Nov Santé and Bpifrance as well as Aridian, Mérieux Equity Partners, and Eximium.
President of SEQENS, Pierre Luzeau, said that the combination of the knowledge, products, and technologies of Wavelength Pharmaceuticals and the support of its shareholders will enable the company to accelerate the development of its new products and further strengthen its abilities to support its customers in the development of their own products.
The new facility is expected to be completed in October of this year.